Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 12,265 | 6,846 | 8,012 | 18 | 194 |
| Receivables | 442 | 87 | 75 | N/A | N/A |
| Other current assets | 25 | 32 | 9 | 0 | 24 |
| TOTAL | $15,663 | $8,921 | $8,358 | $228 | $348 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 755 | 796 | 838 | 12,752 | 4 |
| TOTAL | $755 | $796 | $838 | $12,752 | $4 |
| Total Assets | $16,417 | $9,718 | $9,196 | $12,980 | $352 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | N/A | 670 |
| Accounts payable and accrued liabilities | 301 | 472 | 3,141 | 319 | 1,725 |
| Accrued Expenses | 3,408 | 3,731 | 412 | N/A | 345 |
| TOTAL | $16,482 | $7,032 | $4,029 | $319 | $7,010 |
| Non-Current Liabilities | |||||
| Long Term Debt | 4,441 | 2,115 | N/A | 460 | N/A |
| Other Non-Current Liabilities | 3,653 | 993 | 22 | 10,311 | 196 |
| TOTAL | $8,094 | $3,072 | $N/A | $10,767 | $N/A |
| Total Liabilities | $24,575 | $10,103 | $4,029 | $11,087 | $7,010 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 8 | 7 | 7 | 2 | 2 |
| Common Shares | 0 | 2 | 2 | 1 | 2 |
| Retained earnings | -85,846 | -75,006 | -57,842 | -2,919 | -55,959 |
| Other shareholders' equity | -280 | -280 | -244 | 0 | -218 |
| TOTAL | $-8,158 | $-385 | $5,167 | $1,894 | $-6,658 |
| Total Liabilities And Equity | $16,417 | $9,718 | $9,196 | $12,980 | $352 |